GlassScriptPhysician profile
Claudia A Panzer
NPI 1538122007
$3,336.39
in general payments reported to CMS, 2019-2025
24 companies · $405 in 2025
The $405 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $899 · 2020: $171 · 2021: $447 · 2022: $366 · 2023: $507 · 2024: $542 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.02 |
| Education | $117.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $549.18 | 2021-2025 | Unithroid |
| Medtronic, INC. | $493.54 | 2024-2025 | Minimed 780g |
| Senseonics, Incorporated | $400.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $292.66 | 2022-2025 | Strensiq |
| Lilly USA, LLC | $261.90 | 2022-2025 | Mounjaro, Trulicity, Jardiance |
| Radius Health, INC. | $246.36 | 2019 | |
| Mannkind Corporation | $222.95 | 2021-2025 | |
| Amgen INC. | $210.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.33 | 2021 | |
| Vertical Pharmaceuticals, LLC | $129.13 | 2019-2020 | |
| Novo Nordisk INC | $112.56 | 2021 | |
| Currax Pharmaceuticals LLC | $75.00 | 2023 | Nexletol |
| Abbvie INC. | $27.31 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $25.46 | 2025 | |
| Amarin Pharma, INC. | $23.23 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Ibsa Pharma INC. | $16.56 | 2020 | |
| Cequr Corporation | $15.87 | 2024 | Cequr Simplicity |
| Antares Pharma, INC. | $15.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.85 | 2024 | Farxiga |
| Tandem Diabetes Care, INC. | $14.70 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $13.50 | 2019 | |
| Insulet Corporation | $12.79 | 2022 | |
| Dexcom, INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Panzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.